Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given an average rating of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $10.00.

RVPH has been the topic of a number of research reports. D. Boral Capital dropped their target price on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 target price on the stock. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, January 10th. Finally, HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at $25,000. Cornerstone Select Advisors LLC acquired a new position in Reviva Pharmaceuticals during the 4th quarter valued at about $32,000. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth approximately $36,000. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals in the fourth quarter valued at approximately $45,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Reviva Pharmaceuticals by 848.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after acquiring an additional 23,953 shares during the period. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.56 on Thursday. The company has a market capitalization of $18.78 million, a price-to-earnings ratio of -0.51 and a beta of -0.09. Reviva Pharmaceuticals has a one year low of $0.50 and a one year high of $4.28. The stock has a 50-day simple moving average of $1.46 and a 200 day simple moving average of $1.46.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, equities research analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.